uniQure N.V.
NASDAQ:QURE · NASDAQ Global Select
-$1.13 today
Vol 4.35M · Avg 1.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-100.0%
avg 266.1%
ROIC
-24.5%
avg -26.3%
ROA
-24.1%
avg -25.7%
Analysis
ROA is currently the strongest return metric at -24.1% versus its period average of -25.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Matthew Craig Kapusta | Chief Executive Officer & Executive Director | $1.05M | — | 54 | $675,239.00 | 1.07% |
Walid Abi-Saab | Chief Medical Officer | $945,278.00 | — | 61 | $214,669.00 | 0.34% |
Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site | $759,950.00 | — | 53 | $238,581.00 | 0.38% |
Richard Porter | Chief Business & Scientific Officer | $732,169.00 | — | 58 | — | — |
Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary | $712,827.00 | — | 64 | $133,246.00 | 0.21% |
Chiara Elizabeth Russo | Senior Director of Investor Relations | — | — | — | — | — |
Amin Abujoub | Chief Technical Operations Officer | — | — | — | — | — |
Tamara Tugal | Business Development Director | — | — | — | — | — |
Erin Boyer | Chief People & Culture Officer | — | — | — | — | — |
Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | — | — | — | — | — |
Kylie O'Keefe | Chief Customer & Strategy Officer | — | — | 41 | $108,864.00 | 0.17% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
43
$17.13M
Net Sentiment
$17.13M
Net selling
Most Active
Gut Robert
9 transactions
1–10 of 43
Analysis
Insiders reported 0 buys worth $0.00 and 43 sells worth $17.13M over the last 12 months. That adds up to net selling of $17.13M. Gut Robert was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +29.5% (15yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +29.5% (15yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.83B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.65B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.50B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.19B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$2.10B
Nuvation Bio Inc.
NYSE:NUVB
$1.89B
Galapagos N.V.
GLPG
$1.84B
Mesoblast Limited
NASDAQ:MESO
$1.84B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.67B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.50B
Who manages QURE?
uniQure N.V. (QURE) lists 11 active executives. The top listed executive is Richard Porter, Chief Business & Scientific Officer.
Are QURE insiders buying or selling?
Recent insider activity shows net selling of $6.41M.
Explore More
Continue the stock analysis
Jump to another research area for this company.